Will the FDA Panel Vote Make NAD+ a Mainstream Anti-Aging Therapy?
The Current Status of NAD+ in the Anti-Aging Conversation
Nicotinamide adenine dinucleotide (NAD+) has been a fixture of longevity research for decades. It is a coenzyme found in every living cell, central to energy metabolism and cellular repair. In recent years, the molecule has moved from the pages of biochemistry journals into the supplement aisles, driven by a wave of popular science coverage and a growing market for NAD+ precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). The question now is whether a recent FDA advisory panel vote will push NAD+ from a niche interest into something resembling a mainstream anti-aging therapy.
The panel, convened in late 2024, was not asked to approve NAD+ itself as a drug. Instead, it reviewed the regulatory status of NMN, a compound that the body converts into NAD+. The vote was narrow, and the outcome left many observers uncertain about the immediate path forward. But the conversation it started has already shifted expectations. Researchers, investors, and consumers are now asking what the science actually says about NAD+ and aging, and whether other peptides and small molecules might offer complementary or alternative routes to the same goals.
How NAD+ Functions in the Body
NAD+ exists in two forms: oxidized (NAD+) and reduced (NADH). The ratio between them is critical for mitochondrial function. NAD+ accepts electrons during glycolysis and the citric acid cycle, becoming NADH. That NADH then donates electrons to the electron transport chain, driving ATP production. Without sufficient NAD+, the entire process slows. Cells lose their ability to generate energy efficiently.
But NAD+ is not just a metabolic shuttle. It is also a substrate for enzymes that govern DNA repair, stress resistance, and circadian rhythms. The sirtuins, a family of proteins linked to longevity in model organisms, require NAD+ to remove acetyl groups from other proteins. Poly(ADP-ribose) polymerases (PARPs), which detect and signal DNA strand breaks, consume NAD+ as they build poly(ADP-ribose) chains. CD38, an enzyme expressed on immune cells, breaks down NAD+ and its precursor NMN. As organisms age, NAD+ levels decline, sometimes by as much as 50% in certain tissues (Covarrubias et al. 2021). This decline correlates with many hallmarks of aging: mitochondrial dysfunction, genomic instability, and loss of proteostasis.
What the Research Shows About NAD+ Restoration
Most human data on NAD+ restoration comes from studies of NR and NMN. These precursors are orally available and raise NAD+ levels in blood and, to a lesser extent, in tissues. A randomized trial of NR in older adults found a modest increase in NAD+ and a small improvement in blood pressure and arterial stiffness (Martens et al. 2018). Another study in postmenopausal women with prediabetes reported improved insulin sensitivity after 10 weeks of NMN supplementation (Yoshino et al. 2021). These results are encouraging but limited. The effect sizes are small, and the studies are short. No trial has yet shown that raising NAD+ extends human lifespan or prevents age-related disease in a definitive way.
Animal studies paint a more dramatic picture. In mice, NMN supplementation reverses age-related declines in muscle function, cognitive performance, and vascular health (Mills et al. 2016). But rodents are not humans. Their NAD+ metabolism differs in key respects, including the expression and activity of CD38. Human CD38 levels rise sharply with age, while mouse CD38 does not (Camacho-Pereira et al. 2016). This means that simply boosting NAD+ precursors may not be enough in older humans. The problem may be excessive consumption of NAD+, not just insufficient production.
Some researchers have turned to alternative strategies. Inhibiting CD38 with small molecules or flavonoids like apigenin has shown promise in preclinical models (Escande et al. 2013). Others focus on activating sirtuins directly, using compounds like resveratrol or synthetic STACs. These approaches are less developed than precursor supplementation, but they address the other side of the NAD+ equation.
The FDA Panel Vote and Its Implications
In November 2024, the FDA's advisory panel voted on whether NMN should be excluded from the definition of a dietary supplement. The background is complicated. In 2022, the agency determined that NMN was first investigated as a drug, which under the Federal Food, Drug, and Cosmetic Act can preclude its sale as a supplement. The panel's vote was split, and the FDA has not yet issued a final decision. But the mere fact of the vote has already affected the market. Several major retailers paused NMN sales. Supplement manufacturers are reformulating products. The uncertainty is pushing some consumers toward NR, which remains on the market, or toward injectable NAD+ itself, which exists in a regulatory gray area.
If the FDA ultimately restricts NMN, it could accelerate interest in other compounds that influence NAD+ metabolism indirectly. This is where peptides like GHK-Cu, Epitalon, and thymic peptides enter the picture. None of these are NAD+ precursors, but they intersect with aging pathways in ways that may complement NAD+ restoration.
Peptides That Intersect With NAD+ Biology
GHK-Cu is a copper-binding tripeptide that declines with age. It is involved in wound healing, tissue remodeling, and gene expression. Recent work suggests that GHK-Cu can influence epigenetic aging clocks, which measure DNA methylation patterns to estimate biological age. In cell culture, GHK-Cu has been shown to reset some of these patterns, shifting cells toward a more youthful profile. This is relevant because sirtuins, which depend on NAD+, are also epigenetic regulators. They deacetylate histones and transcription factors, altering gene expression. There is no direct evidence that GHK-Cu and NAD+ interact, but the overlap in their downstream effects is striking. For more on this, see how GHK-Cu and Epitalon work together on epigenetic aging clocks.
Epitalon is a synthetic tetrapeptide based on a sequence from epithalamin, a pineal gland extract. It has been studied primarily in Russia for its effects on telomere length and circadian rhythms. Telomeres, the protective caps on chromosome ends, shorten with each cell division. Epitalon appears to activate telomerase, the enzyme that rebuilds them. This is a different mechanism from NAD+ restoration, but it targets the same ultimate problem: cellular aging. Some researchers have proposed that combining Epitalon with GHK-Cu could produce synergistic effects on both telomeres and the epigenome. A deeper look at this combination is available in the article on GHK-Cu and Epitalon synergy for telomere support and epigenetic rejuvenation.
Thymalin and its synthetic analogue Thymogen are thymic peptides that modulate immune function. The thymus gland shrinks with age, a process called involution. This leads to a decline in naive T-cell production and a corresponding rise in immune senescence. Thymalin has been used in clinical settings in Russia to restore immune function in older adults and in patients with acute infections. In animal models, it extends lifespan and reduces cancer incidence (Anisimov et al. 2003). The connection to NAD+ is indirect. Immune cells, particularly those expressing high levels of CD38, are major consumers of NAD+. Age-related immune activation drives NAD+ depletion. By calming this immune hyperactivity, thymic peptides might help preserve NAD+ levels. The interplay between GHK-Cu and Thymalin for immune rejuvenation is explored in this article on GHK-Cu and Thymalin synergy.
Vesugen and Cortagen are less well-known. Vesugen is a synthetic peptide designed to support vascular health. It was developed by the same Russian research group that created Epitalon. Cortagen targets brain function and has been studied for cognitive decline. Neither peptide has a direct link to NAD+ metabolism, but both address tissue-specific aging processes that NAD+ also influences. Vascular aging, for instance, involves endothelial dysfunction and arterial stiffening, both of which are improved by NAD+ restoration in animal models. Cortagen's effects on neuronal survival and synaptic plasticity overlap with sirtuin-mediated neuroprotection. These parallels are intriguing but remain speculative without direct comparative studies.
Practical Considerations for Researchers and Clinicians
For those following the science, the current landscape presents several challenges. First, the quality of available NAD+ precursors varies widely. Third-party testing has found that some NMN and NR supplements contain far less active ingredient than claimed. Researchers should verify purity and concentration through independent lab analysis before using any compound in a study.
Second, dosing protocols for peptides like GHK-Cu, Epitalon, and Thymalin are not standardized. The Russian studies that form the bulk of the evidence base used specific regimens that may not translate directly to other populations. For example, Epitalon is often administered in 10-day courses repeated every 6 months. GHK-Cu is typically used at something like 1-2 mg per day, either subcutaneously or topically. These protocols are based on empirical observation, not pharmacokinetic modeling. Anyone designing a trial or self-directed research project should review the original papers carefully.
Third, the regulatory environment is shifting. The FDA's NMN decision could set a precedent for other compounds that were first investigated as drugs. Peptides like Epitalon and Thymalin exist in a similar gray area. They have been studied as pharmaceuticals in Russia but are sold as research chemicals or supplements elsewhere. This creates legal risk for manufacturers and uncertainty for consumers.
Open Questions and Future Directions
The biggest open question is whether raising NAD+ levels alone is sufficient to slow human aging. The decline in NAD+ with age is well-documented, but it is not clear whether this decline is a cause or a consequence of aging. It may be both. A systems-level approach that combines NAD+ restoration with other interventions, such as senolytics, epigenetic reprogramming, or immune rejuvenation, might be more effective than any single agent.
Another question is how to measure success. Lifespan studies in humans are impractical. Researchers rely on surrogate endpoints like epigenetic clocks, inflammatory markers, and functional tests. But these surrogates are not yet validated as predictors of longevity. The field needs better biomarkers that can track biological age in real time and respond to interventions within a reasonable study period.
The role of the microbiome is also understudied. Gut bacteria produce NAD+ precursors and may influence systemic NAD+ levels. Dietary interventions that shift the microbiome could enhance or undermine the effects of supplementation. This is an area where rigorous human data is almost entirely absent.
Finally, the interaction between NAD+ and the peptides discussed here is largely unexplored. No published study has tested GHK-Cu, Epitalon, and NMN together in any model. The theoretical synergies are compelling, but theory is not evidence. Collaborative research that bridges the NAD+ and peptide communities could open new avenues for intervention.
Side-effect and adverse-event data for many peptides is sparse. Absence of reported harm does not equate to absence of risk.